Extended-Spectrum Beta-Lactamase Detection with Different Panels for Automated Susceptibility Testing and with a Chromogenic Medium

ABSTRACT Infections caused by extended-spectrum beta-lactamase (ESBL)- and ampC beta-lactamase-producing gram-negative bacteria complicate therapy and limit treatment options. Several different panels for ESBL detection with automated systems exist. In addition, a chromogenic agar medium is available for ESBL screening. We compared two automated identification and susceptibility testing systems with regard to their effectiveness in detecting ESBL production in Enterobacteriaceae: the BD Phoenix system (BD Diagnostic Systems, Sparks, MD) and the Vitek 2 system (bioMerieux, Marcy l'Etoile, France). We tested 114 strains using the Etest as the standard, various available panels for both automated systems (for BD Phoenix, the NMIC/ID-50 and NMIC/ID-70 GN Combo panels for combined identification and susceptibility testing of gram-negative bacilli, and for Vitek 2, the ID-GNB panel for identification of gram-negative bacilli and the AST-N020, AST-N041, and AST-N062 panels for susceptibility testing), and a chromogenic agar medium (bioMérieux, Marcy l'Etoile, France). PCR for common ESBL gene families (encoding TEM, SHV, OXA, and CTX-M) and for chromosomal or plasmid-mediated ampC beta-lactamase genes was conducted to complete the study design. For the tested specimens overall, the chromID ESBL agar showed the highest sensitivity (95.8%) but the lowest specificity (10.5%) compared to the sensitivity and specificity of the Etest (chosen as reference by the authors) for the detection of ESBL-producing strains. The BD Phoenix system showed sensitivities of 77.1% and 84.2% and specificities of 61.5% and 75.0%, respectively, for the NMIC/ID-50 andNMIC/ID-70 panels. The sensitivity of the Vitek 2 system ranged from 78.8% (AST-N020) to 80.6% (AST-N062) and up to 84.2% (AST-N041). The specificities of the respective panels were 50.0% (AST-N041 and AST-N062) and 55.6% (AST-N020). In conclusion, the sensitivities and specificities of ESBL detection by the different methods differ depending on the microorganisms under study.

[1]  R. Ramphal,et al.  Extended-Spectrum β-Lactamases and Clinical Outcomes: Current Data , 2006 .

[2]  Y. Glupczynski,et al.  Evaluation of a New Selective Chromogenic Agar Medium for Detection of Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae , 2006, Journal of Clinical Microbiology.

[3]  P. Nordmann,et al.  Biochemical analysis of the ceftazidime-hydrolysing extended-spectrum beta-lactamase CTX-M-15 and of its structurally related beta-lactamase CTX-M-3. , 2002, The Journal of antimicrobial chemotherapy.

[4]  Armand Paauw,et al.  Evaluation of the Etest ESBL and the BD Phoenix, VITEK 1, and VITEK 2 Automated Instruments for Detection of Extended-Spectrum Beta-Lactamases in Multiresistant Escherichia coli and Klebsiella spp , 2002, Journal of Clinical Microbiology.

[5]  S. Covan,et al.  Two-Center Collaborative Evaluation of Performance of the BD Phoenix Automated Microbiology System for Identification and Antimicrobial Susceptibility Testing of Gram-Negative Bacteria , 2006, Journal of Clinical Microbiology.

[6]  D. Mack,et al.  Evaluation of a new cefepime-clavulanate ESBL Etest to detect extended-spectrum beta-lactamases in an Enterobacteriaceae strain collection. , 2004, The Journal of antimicrobial chemotherapy.

[7]  J. Barry,et al.  Comparative evaluation of the VITEK 2 Advanced Expert System (AES) in five UK hospitals. , 2003, The Journal of antimicrobial chemotherapy.

[8]  H. Goossens,et al.  International Prospective Study of Klebsiella pneumoniae Bacteremia: Implications of Extended-Spectrum -Lactamase Production in Nosocomial Infections , 2004, Annals of Internal Medicine.

[9]  M. Frosch,et al.  Comparative evaluation of a new Vitek 2 system for identification and antimicrobial susceptibility testing of Streptococcus pneumoniae , 2006, European Journal of Clinical Microbiology and Infectious Diseases.

[10]  J. Lucet,et al.  Control of a prolonged outbreak of extended-spectrum beta-lactamase-producing enterobacteriaceae in a university hospital. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  C. O'hara Evaluation of the Phoenix 100 ID/AST System and NID Panel for Identification of Enterobacteriaceae, Vibrionaceae, and Commonly Isolated Nonenteric Gram-Negative Bacilli , 2006, Journal of Clinical Microbiology.

[12]  D. Mack,et al.  Comparison of BDPhoenix and VITEK2 automated antimicrobial susceptibility test systems for extended-spectrum beta-lactamase detection in Escherichia coli and Klebsiella species clinical isolates. , 2003, Diagnostic microbiology and infectious disease.

[13]  D. Livermore,et al.  CTX-M: changing the face of ESBLs in the UK. , 2005, The Journal of antimicrobial chemotherapy.

[14]  P. Vandamme,et al.  Comparative Evaluation of the BD Phoenix and VITEK 2 Automated Instruments for Identification of Isolates of the Burkholderia cepacia Complex , 2002, Journal of Clinical Microbiology.

[15]  Maurizio Sanguinetti,et al.  Characterization of Clinical Isolates of Enterobacteriaceae from Italy by the BD Phoenix Extended-Spectrum β-Lactamase Detection Method , 2003, Journal of Clinical Microbiology.

[16]  N. Hanson,et al.  Detection of Plasmid-Mediated AmpC β-Lactamase Genes in Clinical Isolates by Using Multiplex PCR , 2002, Journal of Clinical Microbiology.

[17]  L. Bret,et al.  Chromosomally Encoded AmpC-Type β-Lactamase in a Clinical Isolate of Proteus mirabilis , 1998, Antimicrobial Agents and Chemotherapy.

[18]  Yehuda Carmeli,et al.  Utility of the VITEK 2 Advanced Expert System for Identification of Extended-Spectrum β-Lactamase Production in Enterobacter spp , 2006, Journal of Clinical Microbiology.

[19]  J. Ariza,et al.  Epidemiology and Successful Control of a Large Outbreak Due to Klebsiella pneumoniae Producing ExtendedSpectrum β-Lactamases , 1998, Antimicrobial Agents and Chemotherapy.

[20]  J. Bartlett International prospective study of klebsiella pneumoniae bacteremia: Implications of extended-spectrum β-lactamase production in nosocomial infections , 2004 .

[21]  Kenneth S. Thomson,et al.  Comparison of Phoenix and VITEK 2 Extended-Spectrum-β-Lactamase Detection Tests for Analysis of Escherichia coli and Klebsiella Isolates with Well-Characterized β-Lactamases , 2007, Journal of Clinical Microbiology.

[22]  N. Woodford,et al.  CTX-M: changing the face of ESBLs in Europe. , 2006, The Journal of antimicrobial chemotherapy.

[23]  Victor L. Yu,et al.  Outcome of Cephalosporin Treatment for Serious Infections Due to Apparently Susceptible Organisms Producing Extended-Spectrum β-Lactamases: Implications for the Clinical Microbiology Laboratory , 2001, Journal of Clinical Microbiology.

[24]  M. Bonora,et al.  Evaluation of the VITEK 2 System for Identification and Antimicrobial Susceptibility Testing of Medically Relevant Gram-Positive Cocci , 2002, Journal of Clinical Microbiology.

[25]  R. Ramphal,et al.  Extended-spectrum beta-lactamases and clinical outcomes: current data. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  Harald Seifert,et al.  Detection of Extended-Spectrum Beta-Lactamases among Enterobacteriaceae by Use of Semiautomated Microbiology Systems and Manual Detection Procedures , 2007, Journal of Clinical Microbiology.

[27]  Marianne Abele-Horn,et al.  Validation of VITEK 2 Version 4.01 Software for Detection, Identification, and Classification of Glycopeptide-Resistant Enterococci , 2006, Journal of Clinical Microbiology.

[28]  M. Jackson,et al.  Management of multidrug-resistant organisms in health care settings, 2006. , 2007, American journal of infection control.

[29]  S. Mitsuhashi,et al.  Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens , 1983, Infection.